Pancreatic Islet Cell Transplantation - (0107) — MM 0107 | CIGNA Coverage Update

TL;DR: Cigna Healthcare modified MM 0107 covering pancreatic islet cell transplantation, effective September 26, 2025. Here's what billing teams need to know before submitting claims under CPT codes 0584T, 0585T, 0586T, and 48160 — and why one HCPCS code on this list is a guaranteed denial.

Cigna Healthcare updated its pancreatic islet cell transplantation coverage policy under policy code MM 0107 in the Cigna system, with an effective date of September 26, 2025. The policy covers eight codes total — four CPT and four HCPCS — but not all of them carry the same coverage status. If your team bills S2102 for allogeneic islet cell tissue transplant, stop now. That code is classified as Experimental/Investigational/Unproven, and Cigna will not reimburse it.

Quick-Reference Table

Cigna Pancreatic Islet Cell Transplantation Coverage Criteria and Medical Necessity Requirements 2025

The Cigna pancreatic islet cell transplantation coverage policy draws a clear line between two very different procedures. One is autologous transplantation — where a patient's own islet cells are harvested, typically after a total or near-total pancreatectomy, and then reinfused. The other is allogeneic transplantation, where islet cells come from a donor pancreas.

Cigna considers autologous pancreatic islet cell transplantation medically necessary when the applicable clinical criteria are met. CPT 48160 — pancreatectomy, total or subtotal, with autologous transplantation of pancreatic islet cells — falls into this covered category. So do the islet cell transplant procedure codes 0584T, 0585T, and 0586T, along with HCPCS codes G0341, G0342, and G0343.

Medical necessity documentation is not optional here. These procedures are high-cost, high-scrutiny, and Cigna will look for clinical justification in the record. Expect prior authorization requirements for all covered codes in this policy — this is not a procedure category where you submit and hope. If you're not sure what prior auth documentation Cigna requires for your specific patient population, talk to your compliance officer before the September 26, 2025 effective date passes.

The real risk in pancreatic islet cell transplantation billing is the allogeneic side. HCPCS S2102, which represents islet cell tissue transplant from a donor pancreas, carries an Experimental/Investigational/Unproven designation. Cigna does not consider this procedure proven for reimbursement. That classification does not change with this policy modification — it's a wall, not a gray area.

Cigna Pancreatic Islet Cell Transplantation Exclusions and Non-Covered Indications

S2102 is the code to watch. Cigna classifies allogeneic islet cell tissue transplant — HCPCS S2102 — as Experimental/Investigational/Unproven. That designation means no reimbursement under the standard Cigna pancreatic islet cell transplantation coverage policy, regardless of the clinical circumstances.

This is not a new position for Cigna. Allogeneic islet transplantation has faced payer resistance for years because long-term outcomes data and FDA approval history have been inconsistent. Cigna's position here is consistent with how many commercial payers treat this procedure. That doesn't make the denial any less painful for your revenue cycle — it just means you shouldn't be surprised when it comes.

If a patient or physician is pushing for allogeneic transplant and asking your billing team to submit S2102, have a direct conversation about coverage before the procedure happens. A claim denial after the fact is far harder to resolve than a financial counseling conversation before. If your practice is in a position where you believe S2102 should be covered based on a patient's individual circumstances, route that to your compliance officer or billing consultant before submission.

Coverage Indications at a Glance

Cigna Pancreatic Islet Cell Transplantation Billing Guidelines and Action Items 2025

CPT, HCPCS, and ICD-10 Codes for Pancreatic Islet Cell Transplantation Under MM 0107

Covered CPT Codes (When Medical Necessity Criteria Are Met)

Covered HCPCS Codes (When Medical Necessity Criteria Are Met)

Experimental / Investigational / Unproven — Not Covered

Note: No ICD-10-CM codes are listed in the Cigna MM 0107 policy data. Work with your coding team to assign the appropriate diagnosis codes based on clinical documentation — typically chronic pancreatitis or related conditions driving the pancreatectomy and autologous transplant.

A practical note on the CPT 0584T, 0585T, and 0586T codes: the published policy data truncates the full descriptors for all three. Before September 26, 2025, pull the complete AMA CPT code book descriptions and confirm with your coding team how Cigna's internal policy differentiates between them. Billing the wrong code in a series like this — where the procedures are clinically similar but coded differently — is the kind of error that triggers a post-payment review. Don't leave that to chance.

This policy sits at the intersection of transplant surgery and endocrinology billing. Your transplant coordinators, OR coding staff, and revenue cycle team all need to be aligned on the approach-code mapping and the autologous-versus-allogeneic distinction. If your organization handles both procedure types, the S2102 exclusion needs to be a standing part of your pre-service financial clearance workflow — not an afterthought.